ClinicalTrials.gg
RecruitingNCT07016490Updated Jan 28, 2026

A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors

A Phase 1 interventional study of SSGJ-709 in Advanced Malignant Tumors, sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. Recruiting at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Shenyang Sunshine Pharmaceutical Co., LTD. (part of 3SBio Inc.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is an open-label phase I study to evaluate the safety, pharmacokinetics, and anti-tumor activity of SSGJ-709 as a single agent in patients with advanced malignancies.

Read the detailed description

The goal of this clinical trial is to learn more about a new drug called SSGJ-709 . The primary aim of this clinical trial is to test the safety of SSGJ-709 at different dose levels on patients with advanced malignant tumors. The clinical trial consists of two phases. The dose escalation phase involves the process of gradually increasing the amount of drug given to find the highest dose that is safe and effective. The dose expansion phase involves the process of giving a drug at a specific dose to a larger group of participants to further evaluate its safety and effectiveness.

Participants will:

  1. Receive SSGJ-709 infusion once every 3 weeks
  2. Visit the clinic once every 3 weeks for checkups and tests
02

Conditions studied

  • Advanced Malignant Tumors
03

In context

Lead sponsor

Shenyang Sunshine Pharmaceutical Co., LTD. is the lead sponsor of 40 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minimum of 3 months;
  • (ECOG) Performance status (PS) score of 0-1;
  • Locally advanced or malignant tumors confirmed by histopathology or cytology; preferred tumor types for enrollment include head and neck squamous cell carcinoma, non-small cell lung cancer, esophageal squamous cell carcinoma or adenocarcinoma, gastric or gastroesophageal junction adenocarcinoma, colorectal adenocarcinoma, hepatocellular carcinoma, urothelial carcinoma, and clear cell renal cell carcinoma. Subjects with other tumor types may be enrolled after discussion with the sponsor;
  • Subject who have failed, or has been intolerant to standard therapy, or has been considered lack standard of care for a given tumor type, and who is not able to complete surgical resection and receive curative concurrent/sequential chemoradiotherapy;
  • Having at least one measurable tumor lesion as the target lesion assessed per v1.1;
  • The subject has adequate hematological and organ functions;

Exclusion criteria

Exclusion Criteria:

  • Presence of brainstem, meningeal , spinal cord metastases or compression;
  • Presence of active central nervous system (CNS) metastases;
  • Subjects with pleural effusion, pericardial effusion, or ascites that are clinically symptomatic or require repeated drainage;
  • Subjects with other malignant tumors within 3 years prior to screening;
  • Subjects with diseases that require systemic treatment within 2 years before screening;
  • Subjects are positive for (HIV);
  • Prior or current presence of non-infectious pneumonia/interstitial lung disease requiring systemic therapy with ;
  • Serious infection within 4 weeks prior to the first dose or the presence of any active infection requiring systemic anti-infective therapy.
  • Having received the following treatments prior to the first dose of study treatment:

    1. Having received anti-tumor therapies such as biological agents, chemotherapy and other drugs not approved for marketing within 3 weeks prior to the first dose of study treatment (Patient may be enrolled if the first dose of study treatment is more than 5 half-lives of the drug from the last anti-tumor therapy);
    2. Having received small molecule targeted antineoplastic agents (e.g., tyrosine kinase inhibitor), or palliative local therapy for non-target lesions, or non-specific immunomodulatory therapy (e.g., interleukin, interferon, thymosin, tumor necrosis factor) within 2 weeks prior to the first dose;
    3. Having received herbal medicine with an anti-tumor indication within 1 week prior to the first dose;
    4. Prior immunotherapy other than anti-PD-(L)1 therapy (Patients with prior immunotherapy against other targets may be enrolled after discussion and agreement with the sponsor).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Experimental: SSGJ-709

    In dose escalation phase, SSGJ-709 will be conducted using accelerated titration and traditional 3+3 design. Dose Escalation Level includes 5 levels, Q3W IV. During or after dose escalation, any dose level that does not exceed the MTD can be expanded.

    Drug: SSGJ-709

Interventions

  • DrugSSGJ-709

    A bispecific antibody targeting PD-1 and LAG-3.

06

What researchers measure

Primary outcomes

  1. Incidence of DLT

    Dose limiting toxicity

    Time frame: 21 days

  2. Incidence of Treatment-Emergent Adverse Events

    TEAE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Cmax of SSGJ-709

    Peak Plasma Concentration

    Time frame: through study completion, an average of 1 year

  2. Tmax of SSGJ-709

    Time to peak drug concentration

    Time frame: through study completion, an average of 1 year

  3. AUC0-last of SSGJ-709

    the area under the curve (AUC) up to the last measurable concentration

    Time frame: through study completion, an average of 1 year

  4. Incidence of ADA

    Number of subjects with detectable anti-drug antibodies (ADA)

    Time frame: through study completion, an average of 1 year

  5. ORR

    ORR ( objective response rate) is the proportion of subjects with complete response(CR) or partial response(PR), evaluated by the investigators per RECIST v1.1

    Time frame: every 6 weeks after first dose, through study completion, an average of 1 year

  6. PFS assessed by investigator per RECIST v1.1

    Progression-free survival (PFS) is defined as the time from the date of randomization till the first documentation of disease progression assessed by the investigator or death due to any cause (whichever occurs first).

    Time frame: through study completion, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Sep 2027, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2025
First posted
Jun 11, 2025
StartActual
Jun 12, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 30, 2027
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07016490
Collaborators
Macquarie University, Australia
Responsible party
Sponsor
First posted
Jun 11, 2025
Start date
Jun 12, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Jan 28, 2026

Study contacts

Andrew Parsonson
Contact
andrew.parsonson@mqhealth.org.au
+61 2 9812 3538
Andrew Parsonson
principal investigator · Macquarie University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion